A 28-week clinical trial in patients with primary hypercholesterolemia or mixed
hyperlipidemia to study the effects of MK0524A on lipids and tolerability. There will be 9
scheduled clinic visits, and 3 treatment groups. A patient can be randomly assigned to 1 of
the 3 treatment groups.